Biologics/Immunotherapy News

Children with severe allergic asthma and serum total IgE levels between 1,500 kU/L and 3,300 kU/L as well as food allergy benefitted from omalizumab, according to a study published in Pediatric Allergy and Immunology.

WASHINGTON — Children were desensitized to baked and unheated milk with 12 and 24 months of baked milk oral immunotherapy, according to a study presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

WASHINGTON — Adults with peanut allergy safely used toothpaste infused with peanut protein as oral mucosal immunotherapy, according to a poster presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

Patients with food allergy who used omalizumab experienced increased thresholds for reacting to peanut and other foods to which they were allergic, according to a study published in The New England Journal of Medicine.

WASHINGTON — Urticaria activity symptom scores improved with barzolvolimab among patients with chronic spontaneous urticaria, according to a presentation at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

Healio has compiled February’s most-read news in asthma and allergy.

WASHINGTON — Omalizumab increased thresholds for reacting to peanut and other common allergenic foods during accidental exposure, according to a study presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

WASHINGTON — Patients with multiple food allergies experienced a protective effect against allergic reactions with omalizumab, according to an abstract presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

WASHINGTON — Robert Wood, MD, FAAAAI, recounted the results of the OUtMATCH study to a standing-room-only crowd at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

The FDA has approved omalizumab for use in building tolerance to accidental ingestion of allergens among patients with IgE-mediated food allergy.